Business
10x Genomics Commercially Launches Xenium Platform for In Situ Analysis
Began global shipments of Xenium Analyzer, the highest throughput instrument for subcellular In Situ profiling PLEASANTON, Calif., Dec. 8, 2022 /PRNewswire/
About this update from 10x Genomics, Inc.
[{"type":"text","content":"Began global shipments of Xenium Analyzer, the highest throughput instrument for subcellular In Situ profiling \nPLEASANTON, Calif., Dec. 8, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the first commercial shipments of its Xenium platform for in situ analysis. Xenium is the next generation of targeted spatial profiling of genes and proteins at subcellular resolution. The platform includes a versatile and easy-to-use instrument, a diverse menu of curated, customizable and high-quality panels, and Xenium Explorer, intuitive software for interactive data visualization. Leveraging its industry-leading speed and throughput, Xenium enables subcellular mapping of hundreds of RNA targets, generating high quality data with high sensitivity and specificity to reveal new insights into cellular structure and function.\n\n \n \n \n \n \n \n\n \n\"We built 10x to deliver technologies to address the complexity of biology, and with the commercial launch of Xenium, we're confident we now have the full set of solutions for the future of biological analysis,\" said Ben Hindson, Co-Founder and Chief Scientific Officer of 10x Genomics. \"We developed Xenium with a unique combination of performance advantages, which are resonating well with customers, and we strongly believe Xenium is the best performing system available for in situ analysis. It is yet another example of how we bring together our multidisciplinary expertise, R&D capabilities and relentless customer focus to solve hard challenges and enable our customers to uncover the deepest biological insights.\"\nNext-generation sequencing and imaging have produced dramatic data and fine-tuned the resolution of cells in action, but both fields have developed separately. The high cellular resolution of Xenium Platform enables researchers to assess the relationship between cellular structure and function, directly in tissue, without the need for sequencing -- bridging the worlds of genomics and pathology.\n\"We didn't want just an instrument that performs an assay well today, but also a platform that will evolve over the next several years and continue to provide valuable insights in situ,\" said Bill Flynn, PhD, Associate Director of Single Cell Biology at The Jackson Laboratory for Genomic Medic...